Soleus Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Soleus Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.51M	Buy	+1,000,000	New	+$3.2M	0.14%	73
2025 Q4	–	Sell	-976,707	Closed	-$2.12M	–	109
2025 Q3	$2.12M	Sell	976,707 -2,285,000	-70%	-$5.4M	0.11%	73
2025 Q2	$5.61M	Sell	3,261,707 -4,523,293	-58%	-$11.3M	0.37%	51
2025 Q1	$25.9M	Buy	7,785,000 +1,225,000	+19%	+$6.32M	1.87%	16
2024 Q4	$48.5M	Sell	6,560,000 -1,968,500	-23%	-$18.2M	3.05%	8
2024 Q3	$80.1M	Buy	8,528,500 +980,500	+13%	+$9.29M	6.2%	2
2024 Q2	$60.5M	Buy	7,548,000 +4,043,000	+115%	+$43.3M	5.34%	2
2024 Q1	$51.9M	Buy	3,505,000 +2,950,000	+532%	+$34.3M	3.86%	4
2023 Q4	$4.51M	Sell	555,000 -684,777	-55%	-$3.58M	0.5%	46
2023 Q3	$5.64M	Hold	1,239,777	–	–	0.52%	49
2023 Q2	$8.73M	Sell	1,239,777 -210,000	-14%	-$1.5M	0.97%	32
2023 Q1	$8.86M	Buy	+1,449,777	New	+$10M	0.92%	30
2022 Q4	–	Sell	-1,025,200	Closed	-$9.82M	–	82
2022 Q3	$9.82M	Buy	1,025,200 +305,600	+42%	+$3.52M	1.33%	25
2022 Q2	$7.94M	Buy	+719,600	New	+$9.43M	1.24%	29

Other funds holding IOVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Soleus Capital Management's IOVA Position: Q1 2026 in Review

Soleus Capital Management opened a new position in Iovance Biotherapeutics (IOVA) in Q1 2026: 1,000,000 shares worth $3.51M. The stake represents 0.14% of the portfolio and ranks #73 among its holdings. This is a return to the name: Soleus Capital Management previously reported a position in IOVA as recently as Q3 2025.

Soleus Capital Management first reported a position in IOVA in Q2 2022 and has held it in 14 quarters since. The position peaked at $80.1M in Q3 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

Soleus Capital Management held 1,000,000 shares of Iovance Biotherapeutics worth $3.51M as of Q1 2026.
Iovance Biotherapeutics was a new Soleus Capital Management position in Q1 2026.
Iovance Biotherapeutics made up 0.14% of Soleus Capital Management's portfolio in Q1 2026, its #73 holding.
Soleus Capital Management first reported a position in Iovance Biotherapeutics in Q2 2022 and has held it in 14 quarters since.
Soleus Capital Management's Iovance Biotherapeutics position peaked at $80.1M in Q3 2024.
285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.